8AK.F Alkermes plc
- Market cap
- EUR 7.21B
- P/E
- -
- P/B
- 4.18x
- ROE
- -5.4%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Sep 2026.
Is 8AK.F undervalued?
Graham numberThe Graham number of Alkermes plc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Alkermes plc fundamental analysis
No fundamental analysis for Alkermes plc yet.
Alkermes plc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Alkermes plc
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neu…
Full company profileAlkermes plc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Alkermes plc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2014 | 2015 | 2016 | 2017 | 2018 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 619M | 628M | 746M | 903M | 1.09B | 1.17B | 1.11B | 1.66B | 1.56B | 1.48B | 1.75B |
| Gross Profit | 443M | 489M | 614M | 749M | 918M | 976M | 894M | 1.41B | 1.31B | 1.28B | 1.43B |
| Operating Income | -87.1M | -224M | -209M | -148M | -99.1M | 97.7M | -6.09M | 414M | 421M | 254M | -23.4M |
| EBITDA | - | - | - | - | - | - | 59.8M | 519M | 495M | 331M | 95.7M |
| Net Income | -30.1M | -227M | -208M | -158M | -139M | -48.2M | -158M | 356M | 367M | 242M | -100M |
| EPS | - | - | - | - | - | -0.30 | -0.96 | 2.13 | 2.26 | 1.46 | -0.60 |
| Balance Sheet | |||||||||||
| Total Assets | 1.92B | 1.86B | 1.73B | 1.80B | 1.83B | 2.02B | 1.96B | 2.14B | 2.06B | 2.49B | 4.44B |
| Total Liabilities | 522M | 541M | 517M | 594M | 654M | 912M | 920M | 934M | 591M | 668M | 2.57B |
| Shareholders' Equity | 1.40B | 1.31B | 1.21B | 1.20B | 1.17B | 1.11B | 1.04B | 1.20B | 1.46B | 1.82B | 1.86B |
| Cash & Short-term Investments | 224M | 181M | 186M | 191M | 267M | 338M | 292M | 457M | 291M | 389M | 631M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 11.1M | -40.4M | -63.8M | 19.2M | 99.3M | 102M | 21.0M | 401M | 439M | 521M | - |
| Capital Expenditure | 33.7M | 52.9M | 43.7M | 51.3M | 69.4M | 29.0M | 38.3M | 48.0M | 33.5M | 40.4M | 9.99M |
| Free Cash Flow | - | - | - | - | - | 72.7M | -17.2M | 353M | 406M | 480M | - |
| Ratios | |||||||||||
| ROE | -2.2% | -17.3% | -17.2% | -13.1% | -11.9% | -4.3% | -15.2% | 29.6% | 25.1% | 13.3% | -5.4% |
| ROA | -1.6% | -12.2% | -12.1% | -8.8% | -7.6% | -2.4% | -8.1% | 16.7% | 17.9% | 9.7% | -2.3% |
| Net Profit Margin | -4.9% | -36.2% | -28.0% | -17.5% | -12.7% | -4.1% | -14.2% | 21.4% | 23.6% | 16.4% | -5.7% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Alkermes plc dividends
Alkermes plc has not paid dividends in the last 9 fiscal years.
Last stock split: 2:1 on May 15, 2000.
Who owns Alkermes plc
- Insiders 1.40%
- Institutions 98.60%
- Public & others 0.00%
- Shares outstanding 168M
- Free float 155M
Alkermes plc company profile
- Company name
- Alkermes plc
- Ticker
- 8AK.F
- ISIN
- IE00B56GVS15
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 2,050
- Fiscal year end
- December
- Address
- Connaught House, Dublin, Ireland, D04 C5Y6
- Phone
- 353 1 772 8000
- Website
- alkermes.com
About Alkermes plc
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Alkermes plc management
10- Mr. Blair C. JacksonPresident, CEO & Director · born 1973
- Mr. Joshua Reed M.B.A.Senior VP & CFO · born 1973
- Mr. David Joseph Gaffin J.D.Executive VP, Chief Legal Officer, Chief Compliance Officer & Secretary · born 1972
- Dr. Craig C. Hopkinson M.D.Executive VP of Research & Development and Chief Medical Officer · born 1969
- Mr. Christian Todd NicholsSenior VP & Chief Commercial Officer · born 1970
- Mr. Samuel J. ParisiInterim Principal Accounting Officer & VP of Finance · born 1975
- Mr. Tom SkoffSVP & Chief Information Officer
- Ms. Sandra CoombsSenior Vice President of Corporate Affairs & Investor Relations
- Mr. Stephen SchiavoSenior VP & Chief Human Resources Officer
- Mr. Peter NormanSVP of Policy, Government & Community Relations